The Institute for Clinical and Economic Review is piloting an approach to making its cost-effectiveness models available to drug manufacturers during reviews to enhance the transparency of its methods.
"ICER is committed to ensuring the highest level of transparency in all our work, and this pilot program takes our...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?